LadRx starts hunt for new life; Statera lines up merger with diagnostics company
The Los Angeles biotech, listed on the over-the-counter market, said it initiated a process looking for a merger, strategic sale, up-listing to Nasdaq or other forms of “maximizing shareholder value.” Roth Capital Partners will advise the company.
“We believe that LadRx has great potential if Arimoclomol and Aldoxorubicin successfully navigate clinical trials and regulatory approvals, and we have additional next-generation oncology drugs in the pipeline,” CEO Stephen Snowdy said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.